Biocon Valuation Multiples

Biocon Overview

About Biocon

Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.

Founded

1978

HQ

Employees

16.6K

Website

biocon.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $2B

EBITDA: $373M

EV

$7B

Valuation Multiples

Multiples.vc

Start free trial

Biocon Financials

Biocon reported last 12-month revenue of $2B and EBITDA of $373M.

In the same LTM period, Biocon generated $1B in gross profit, $373M in EBITDA, and $69M in net income.

Biocon P&L

In the most recent fiscal year, Biocon reported revenue of $2B and EBITDA of $472M.

Biocon expects next 12-month revenue of XXX and NTM EBITDA of XXX

Biocon Stock Performance

Biocon has current market cap of $6B, and enterprise value of $7B.

Biocon's stock price is $3.65.

Biocon Valuation Multiples

Biocon trades at 3.8x EV/Revenue multiple, and 18.7x EV/EBITDA.

Biocon Financial Valuation Multiples

As of April 14, 2026, Biocon has market cap of $6B and EV of $7B.

Equity research analysts estimate Biocon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Biocon has a P/E ratio of 86.3x.

Biocon Margins & Growth Rates

Biocon's revenue in the last 12 month grew by 18%.

Biocon's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Biocon's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Biocon's rule of X is 66% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Biocon Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Biocon M&A Activity

Biocon acquired XXX companies to date.

Last acquisition by Biocon was on XXXXXXXX, XXXXX. Biocon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Biocon Investment Activity

Biocon invested in XXX companies to date.

Biocon made its latest investment on XXXXXXXX, XXXXX. Biocon invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).